AssertioASRT
ASRT
About: Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Employees: 30
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
479% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $181K
2.66% less ownership
Funds ownership: 29.18% [Q4 2024] → 26.52% (-2.66%) [Q1 2025]
17% less funds holding
Funds holding: 82 [Q4 2024] → 68 (-14) [Q1 2025]
29% less capital invested
Capital invested by funds: $24.3M [Q4 2024] → $17.1M (-$7.14M) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 28
82% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 17
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3.50
454%
upside
Avg. target
$3.50
454%
upside
High target
$3.50
454%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 454%upside $3.50 | Buy Reiterated | 19 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025
LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners Healthcare Company Showcase, taking place Wednesday, May 21, 2025.
Neutral
Seeking Alpha
1 month ago
Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Matt Kreps - Investor Relations Brendan O'Grady - Chief Executive Officer Ajay Patel - Chief Financial Officer. Conference Call Participants Thomas Flaten - Lake Street Naz Rahman - Maxim Group Ram Selvaraju - H.C.
Negative
Zacks Investment Research
1 month ago
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
Assertio (ASRT) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.04 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Assertio Reports First Quarter 2025 Financial Results
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook
Neutral
GlobeNewsWire
1 month ago
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025
LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans.
Neutral
GlobeNewsWire
2 months ago
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025.
Neutral
Seeking Alpha
3 months ago
Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Participants James Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets, LLC Naz Rahman - Maxim Group Scott Henry - AGP Operator Thank you for standing by. My name is Eric, and I'll be your conference operator today.
Neutral
GlobeNewsWire
3 months ago
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
3 months ago
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
Neutral
GlobeNewsWire
4 months ago
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio” or the “Company”) common stock issued in exchange for Spectrum Pharmaceuticals, Inc. (“Spectrum”) common stock in connection with Assertio's July 31, 2023 merger with Spectrum (the “Merger”), charging the Company and certain of its current and former senior executives and directors with violations of the federal securities laws (collectively, “Defendants”).
Charts implemented using Lightweight Charts™